Inhibition of RPN2 expression was found to reduce breast cancer malignancy by reducing CD63 glycosylation and modulating translocation of CD63 [10], which is a cell surface glycoprotein with N-linked glycosylation that regulates cell motility, invasion, and cell signaling of tumors [11]. This evidence concerns the gene CD63 and breast cancer.